StockNews.AISignal intelligence
Company intelligence

COO

The Cooper Companies, Inc. · NASDAQ · Healthcare

Price$54.22+0.58% · +$0.31
Market cap10.57BEquity value
P / E11.9Trailing ratio
Volume5.41MLatest session
Market data

COO price chart

TradingView
Related signals
1 min delayed

Browse public COO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

COOSep 10, 2026-1.63% since signal

Cooper Companies posts mixed results and soft guidance, weighing shares

Cooper Cos. reported mixed quarterly results with soft guidance and concluded its strategic review without pursuing a deal. The combination signals near-term earnings pressure and limited growth catalysts, likely keeping the stock under pressure until visibility improves on product performance and margin expansion. The catalyst was the soft guidance and the review outcome, with potential for a modest rebound if execution improves.

View signal analysis
COOSep 10, 2026-15.49% since signal

Cooper Companies cuts FY26 guidance after mixed Q3 results

Cooper Companies posted a mixed Q3 with an EPS beat but revenue miss and a lower FY26 outlook. The weakness centers on CooperVision’s U.S. channel inventory reduction, while CooperSurgical delivered growth and a favorable tax outcome. The stock fell in pre-market trading, and multiple analysts reduced targets, highlighting near-term headwinds despite solid cash flow trajectory.

View signal analysis
COODec 5, 2025-4.87% since signal

Cooper Companies Launches Portfolio Review To 'Unlock Value'

Cooper Companies reported Q4 earnings of $1.15, beating estimates. Sales rose 5% YoY; optimism around financial guidance persists. Formal portfolio review aimed at unlocking long-term value announced. Colleen Jay appointed as new Chair starting January 2026. Analysts raise price targets suggesting strong future performance.

View signal analysis
COONov 15, 2025-1.08% since signal

Jana Partners push to break up Cooper Cos. could change the stock's outlook

Jana Partners seeks strategic alternatives for Cooper, including potential mergers. CooperVision leads the contact lens market despite recent operational challenges. CooperSurgical's investments in women's health services are not yielding expected returns. Declining margins and growth issues prompted a reassessment of Cooper's strategy. Jana argues for separating Cooper's businesses to enhance value and performance.

View signal analysis
COOOct 20, 2025-0.11% since signal

Cooper Cos. Stock Rises as Report Says Activist Investor Takes Stake

Jana Partners acquired a stake in Cooper Companies, advocating for strategic changes. Proposed merger of Cooper's contact-lens division with Bausch + Lomb may occur. Cooper's stock rose 4.2% recently despite a 22% decline in 2025. Investment fund sees potential in separating Cooper's business segments. Jana claims Cooper's two main segments lack necessary synergies.

View signal analysis
Research

Company intelligence